Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

17.88 -0.33 (-1.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
ADMA BIOLOGICS INC (NASDAQ:ADMA) - A Strong Growth Candidate Meeting Minervini's Criteria
ADMA Biologics (NASDAQ:ADMA) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors. 
Via Chartmill
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Strong Growth Stock with Technical Breakout Potential
ADMA Biologics (NASDAQ:ADMA) shows strong growth fundamentals and a technical breakout setup, making it a stock to watch in the biotech sector. 
Via Chartmill
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A High Growth Momentum Stock with Strong Technical Setup
ADMA Biologics (NASDAQ:ADMA) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has outperformed peers and may present a breakout... 
Via Chartmill
How Is The Market Feeling About ADMA Biologics?
Via Benzinga
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Promising Affordable Growth Stock
ADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech... 
Via Chartmill
ADMA BIOLOGICS INC (NASDAQ:ADMA) is not too expensive for the growth it is showing.
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
Earnings Scheduled For May 7, 2025
Via Benzinga
ADMA Biologics Earnings Preview
Via Benzinga
What's Driving the Market Sentiment Around ADMA Biologics?
Via Benzinga
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings
Via Benzinga
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits
The company makes immunoglobulin products using donated plasma. 
Via Investor's Business Daily
Topics Earnings
3 Mid-Cap Medical Stocks Outperforming the Market
Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness. 
Via MarketBeat
Topics Economy
Should you consider ADMA BIOLOGICS INC (NASDAQ:ADMA) for growth investing?
A fundamental analysis of (NASDAQ:ADMA): Exploring growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA). 
Via Chartmill
Peering Into ADMA Biologics's Recent Short Interest
Via Benzinga
Would Mark Minervini consider ADMA BIOLOGICS INC (NASDAQ:ADMA) a top stock pick?
A fundamental and technical analysis of (NASDAQ:ADMA): Exploring ADMA BIOLOGICS INC (NASDAQ:ADMA)'s high growth characteristics. 
Via Chartmill
ADMA Biologics Inc (NASDAQ:ADMA): A Strong Minervini Trend Template Candidate
ADMA Biologics Inc (NASDAQ:ADMA): A Strong Minervini Trend Template Candidate 
Via Chartmill
What's Going On With ADMA Stock Monday?
ADM shares are trading higher Monday after the company announced the FDA's approval of its yield enhancement process. 
Via Benzinga
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Via Benzinga
IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval
The company says a new process will improve its output by 20%, benefitting revenue and earnings later this year. 
Via Investor's Business Daily
Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock.
A fundamental and technical analysis of (NASDAQ:ADMA): Is ADMA BIOLOGICS INC (NASDAQ:ADMA) suited for high growth investing? 
Via Chartmill
Investors seeking growth at a reasonable cost should explore ADMA BIOLOGICS INC (NASDAQ:ADMA).
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
What's Driving the Market Sentiment Around ADMA Biologics?
Via Benzinga
ADMA BIOLOGICS INC (NASDAQ:ADMA) is showing good growth, while it is not too expensive.
NASDAQ:ADMA is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook
CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024. 
Via Stocktwits
Earnings Scheduled For March 3, 2025
Via Benzinga
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter. 
Via Stocktwits
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025. 
Via MarketBeat
Topics ETFs Economy
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86. 
Via Investor's Business Daily
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.